G30
Conditions
Interventions
Group 1: Patients, with mild to moderate Alzheimers dementia, got taken blood for scientific examinations before the antidementia treatment with the AChE-I rivastigmine 4.6 mg / 24h for 4 weeks is sta
Sponsors
Institut für Transfusionsmedizin und Immunologie Abteilung Molekularbiologie, UMM, Medizinische Fakultät Mannheim, Universität Heidelberg
Eligibility
Sex/Gender
All
Age
50 Years to 85 Years
Inclusion criteria
Inclusion criteria: physically healthy patients with Alzheimer's disease (guidelines-based diagnoses), able to give consent form, as well as mentally healthy controls (specialist examination).
Exclusion criteria
Exclusion criteria: coagulation deficits
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Function of nACh-receptors on thrombocytes will be examined by laboratory messures at timepoints T0= before tretment with AchE-I, T1=after 4 weeks treatment with Rivastigmine 4,6 mg/24 hrs transdermal, after 4 weeks treatment with Rivastigmine 9,5 mg/24 hrs transdermal, after 12 weeks treatment with Rivastigmine 9,5 mg/24 hrs transdermal | — |
Secondary
| Measure | Time frame |
|---|---|
| coagulation parameters will be examined by laboratory messures at timepoints T0= before tretment with AchE-I, T1=after 4 weeks treatment with Rivastigmine 4,6 mg/24 hrs transdermal, after 4 weeks treatment with Rivastigmine 9,5 mg/24 hrs transdermal, after 12 weeks treatment with Rivastigmine 9,5 mg/24 hrs transdermal | — |
Countries
Germany
Contacts
Public ContactLucrezia Hausner
Abteilung für GerontopsychiatrieZentralinstitut für Seelische Gesundheit Medizinische Fakultät Mannheim, Universität Heidelberg
Outcome results
None listed